Articles From: LifePoint and Duke Expand Partnership to Advance Healthcare Quality to Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV


2015/1/12
LifePoint Hospitals® (NASDAQ: LPNT) and Duke University Health System have expanded their collaborative effort to create safe highly reliable care by entering into a national quality agreement.
Sign-up for LifePoint and Duke Expand Partnership to Advance Healthcare Quality investment picks
2015/2/12
LifePoint Hospitals, Inc. (NASDAQ: LPNT) today announced results for the fourth quarter and year ended December 31, 2014.
Sign-up for LifePoint Hospitals Reports Fourth Quarter and Year-End 2014 Results investment picks
2015/1/29
LifePoint Hospitals, Inc. (NASDAQ: LPNT) announced today that it will provide an online Web simulcast of its fourth quarter and year-end 2014 conference call on Thursday, February 12, 2015.
Sign-up for LifePoint Hospitals to Broadcast Its Fourth Quarter and Year-End 2014 Conference Call Live on the Internet investment picks
2015/1/6
LifePoint Hospitals, Inc. (NASDAQ: LPNT) today announced that its management will participate in the 33 rd Annual J.P. Morgan Healthcare Conference to be held January 12 – 15, 2015, in San Francisco, California.
Sign-up for LifePoint Hospitals to Participate in 33rd Annual J.P. Morgan Healthcare Conference investment picks
2015/1/14
Lifesize , a division of Logitech (NASDAQ:LOGI) (SIX:LOGN), today announced new enhancements to its award-winning Lifesize® Cloud video conferencing service and the introduction of Lifesize® Icon 400 TM and Lifesize® Icon Flex TM .
Sign-up for Lifesize Empowers Every Person and Every Conference Room With Simple and Stunning Video Collaboration investment picks
2015/2/26
Lifesize , a division of Logitech, (NASDAQ:LOGI) (SIX:LOGN), today announced its Lifesize Community , a customer platform for advice, collaboration, advocacy and industry insights.
Sign-up for Lifesize Unveils New Customer Community investment picks
2015/2/23
Lifetime Brands, Inc. (NasdaqGS:LCUT), a leading global provider of branded kitchenware, tableware and other products used in the home, announced today that it has entered into an asset purchase agreement to acquire the operating assets and to assume certain liabilities of Reed and Barton Corporation, which has filed for bankruptcy protection.
Sign-up for Lifetime Brands Agrees to Acquire Reed & Barton and Amends Credit Agreement investment picks
2014/12/18
Lifetime Brands, Inc. (NasdaqGS:LCUT), a leading global provider of branded kitchenware, tableware and other products used in the home, will present at the Sidoti & Company Emerging Growth Institutional Investor Forum on Monday, January 12, 2015.
Sign-up for Lifetime Brands to Present at Sidoti & Company Investor Forum on January 12, 2015 investment picks
2015/2/4
Revenue During First Six Months of Fiscal Year 2015, Excluding Japan, Increased 4.5% SALT LAKE CITY, Feb.
Sign-up for LifeVantage Announces Second Quarter Fiscal Year 2015 Results investment picks
2015/2/2
- Independent Director Dave S.
Sign-up for LifeVantage Corporation Announces Executive Leadership Change investment picks
2015/1/8
SALT LAKE CITY, Jan.
Sign-up for LifeVantage CSO Presenting at Biochemical Society Keap1/Nrf2 Pathway in Health and Disease Meeting investment picks
2015/2/13
SALT LAKE CITY, Feb.
Sign-up for LifeVantage Multi-dimensional Energy Product AXIO Launches in Japan investment picks
2015/1/20
SALT LAKE CITY, Jan.
Sign-up for LifeVantage to Announce Second Quarter Fiscal Year 2015 Results on February 4, 2015 investment picks
2015/1/5
Kefir Manufacturer's New Brand Campaign Debuts Jan.
Sign-up for Lifeway Foods Celebrates New Campaign By Ringing Opening Bell at NASDAQ investment picks
2014/12/22
Once-niche kefir cultured dairy beverage moves into spotlight with awards show, SNL spots MORTON GROVE, Ill.
Sign-up for Lifeway Foods to Air First National TV Spot During 2015 Golden Globes Broadcast investment picks
2015/1/5
ADVISORY, Jan.
Sign-up for Lifeway Foods, Inc. (Nasdaq: LWAY) to Ring The Nasdaq Stock Market Opening Bell investment picks
2015/2/6
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade ® ), seeking an additional indication for the treatment of pediatric patients (age 1 year and above) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins.
Sign-up for Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade® investment picks
2014/12/22
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Sign-up for Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta® investment picks
2015/1/8
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Melinta Therapeutics reported positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin met the study’s primary objective endpoint of a reduction in the measurement of lesion erythema at the primary infection site at 48- to- 72 hours, the endpoint required by the U.S. Food and Drug Administration (FDA). Delafloxacin also was comparable to vancomycin in the study’s secondary endpoints, including investigator assessment of signs and symptoms of infection at the follow-up visit, a metric required by the European Medicines Agency (EMA).
Sign-up for Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: LifePoint and Duke Expand Partnership to Advance Healthcare Quality to Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent